ESC 365 - Exploring the role of icosapent ethyl based on current clinical evidence.

Open Access

Exploring the role of icosapent ethyl based on current clinical evidence.

Session: Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl

Topic: Treatment

Speaker: Professor J. Jukema (Leiden, NL)

Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amarin Pharma

Event: ESC Preventive Cardiology 2022

Congress Presentation

Add to my library

About the speaker

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

20 presentations

0 follower

4 more presentations in this session

Introduction.

Speaker: Professor U. Laufs (Leipzig, DE)

Assessing residual cardiovascular risk in patients already treated with statin therapy.

Speaker: Professor A. Zambon (Padua, IT)

Icosapent ethyl: what are the most likely mechanisms of benefit?

Speaker: Professor C. Packard (Glasgow, GB)

Discussion.

Access the full session

Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl

Speakers: Professor J. Jukema, Professor U. Laufs, Professor A. Zambon, Professor C. Packard

About the event

ESC Preventive Cardiology 2022

7 April - 9 April 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources